<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCDSA</journal-id><journal-title-group><journal-title>Journal of Cosmetics, Dermatological Sciences and Applications</journal-title></journal-title-group><issn pub-type="epub">2161-4105</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jcdsa.2019.91004</article-id><article-id pub-id-type="publisher-id">JCDSA-90548</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Oral Manifestations of Neurofibromatosis Type 1
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hafida</surname><given-names>Cherifi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Benjamin</surname><given-names>Fournier</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ariane</surname><given-names>Berdal</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Blake</surname><given-names>McAlpin</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ishaï-Yaacov</surname><given-names>Sitbon</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bruno</surname><given-names>Gogly</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Henri Mondor Hospital, Dental Department, Paris Descartes University, Paris, France</addr-line></aff><aff id="aff4"><addr-line>Neuroimmunology Laboratory, Department of Symptom Research, Division of Internal Medicine, 
University of Texas MD Anderson Cancer Center, Houston, USA</addr-line></aff><aff id="aff2"><addr-line>Laboratory of Molecular Oral Pathophysiology, Paris, France</addr-line></aff><aff id="aff3"><addr-line>Rotschild Hospital, Centre de référence MAFACE, Paris Diderot University, Paris, France</addr-line></aff><pub-date pub-type="epub"><day>15</day><month>01</month><year>2019</year></pub-date><volume>09</volume><issue>01</issue><fpage>41</fpage><lpage>55</lpage><history><date date-type="received"><day>10,</day>	<month>January</month>	<year>2019</year></date><date date-type="rev-recd"><day>15,</day>	<month>February</month>	<year>2019</year>	</date><date date-type="accepted"><day>18,</day>	<month>February</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Neurofibromatosis type
   
  1 (NF-1) is a common genetic disorder with a highly variable phenotype. The disease affects both proliferation and differentiation of cells of neurectodermal origin. The presence of tumors is very common like benign nodular neurofibromas. Tumors with unclear prognosis may be present like plexiform neurofibromas whose prognosis is more uncertain. While many organs exhibit pathologies, most commonly affected are the nervous system, skin, gastrointestinal tract and heart. Oral abnormalities are also very common: 72% of NF-1 patients exhibit pathologies in oral mucosa, gums, maxillary and temporomandibular joints, and teeth. The incidence of NF-1 and its relationship to the prevalence of caries ha
  ve
   been discussed in other research
  es
  . It is known that poor oral hygiene plays a key role in the development of periodontal disease and caries. Here we review the oral manifestations of neurofibromatosis type
   
  1 that we illustrate by a patient followed in the center of rare diseases of the hospital Henri Mondor, clinical service in which we work.
 
</p></abstract><kwd-group><kwd>Neurofibromatosis Type 1</kwd><kwd> Genetic Disorder</kwd><kwd> Oral Tumor</kwd><kwd> Jaw Abnormalities</kwd><kwd> Periodontal Disease</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Neurofibromatosis (NF) is a genetic disorder that disrupts the nervous system. It affects preferentially tissues derived from the neural crest [<xref ref-type="bibr" rid="scirp.90548-ref1">1</xref>] . In 1982, Riccardi proposed a classification system for seven different types of NF and an additional grouping of non-classifiable NF [<xref ref-type="bibr" rid="scirp.90548-ref1">1</xref>] . Among these classes, two have been the most well-established: neurofibromatosis type 1 (NF-1, OMIM #162200), also called Recklinghausen disease, and neurofibromatosis type 2 (NF-2, OMIM #101000), which affect the central nervous system. The more common of the two, NF-1, was first described by Friedrich Daniel Recklinghausen in 1882. NF-1 is an autosomal dominant genetic disorder that affects 1 birth in 3000; regardless of gender or race [<xref ref-type="bibr" rid="scirp.90548-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref3">3</xref>] , it is caused by mutation of the NF1 gene. In 50% of cases the disease is caused by spontaneous mutation with no family history of NF [<xref ref-type="bibr" rid="scirp.90548-ref4">4</xref>] . NF1 is a tumor-suppressor gene located on the long arm of chromosome 17, in the pericentromeric region at position 11.2 (17q11.2). The gene extends over about 350 kilobases with 57 constitutive exons and 3 alternative exons. Here we describe the structure of the gene involved in the pathology. The NF1 gene can be mutated in several ways either as a deletion, insertion, nonsense or missense mutation [<xref ref-type="bibr" rid="scirp.90548-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref6">6</xref>] . The different mutations result in different clinical situations [<xref ref-type="bibr" rid="scirp.90548-ref7">7</xref>] . The gene product is Neurofibromin which is a 220 kDa cytoplasmic protein of 2818 amino acids belonging to the GTPase Activating Protein (GAP) family protein. Indeed, there is a 360 amino acids domain corresponding to a GAP related domain (GRD). The protein produced by the abnormal NF1 gene of neurofibromatosis is therefore neurofibromin. Neurofibromin is produced by many cell types, particularly by neurons and neuroglia (oligodendrocytes and Schwann cells) and epidermal cells (keratinocytes and melanocytes) [<xref ref-type="bibr" rid="scirp.90548-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref9">9</xref>] . It inhibits the ras signal transduction pathway via negative regulation of a ras GTPase and thus controls cell growth [<xref ref-type="bibr" rid="scirp.90548-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref11">11</xref>] . Neurofibromin signaling induces the transformation of the active form, p21ras-GTP, to the inactive form, p21ras-GDP. The tumor-suppressing function of neurofibromin is achieved via this regulation of active and inactive forms of p21ras. Thus, mutations in NF1 inhibit its tumor-suppressing function and lead to tumor formation. These tumors are characteristic of NF1. However, in some cases of NF-1 patients, no mutations were detected. There may be a disorder in the RNA maturation in the splicing. The pathology of NF-1 is different depending on NF1 mRNA editing [<xref ref-type="bibr" rid="scirp.90548-ref12">12</xref>] . Four different isoforms of NF1 gene have been described; the two most well-known are isoform 1 (GRD1) and isoform 2 (GRD2). Their mRNAs differ by the alternate splicing of a single exon of 63 bp [<xref ref-type="bibr" rid="scirp.90548-ref13">13</xref>] : GRD2 has 21 additional amino-acids in the GRD domain comparatively with GRD1. These two isoforms have a significantly similar distribution throughout tissues. Isoform 3, which differs from the isoform 1 by the presence of 18 additional amino acids in the C-Terminal, is present almost exclusively in cardiac, smooth and skeletal muscle tissue [<xref ref-type="bibr" rid="scirp.90548-ref14">14</xref>] . Isoform 4 contains 10 more amino acids than isoform 1 and is mainly located in the central nervous system [<xref ref-type="bibr" rid="scirp.90548-ref14">14</xref>] . It has been demonstrated that a change from isoform 1 to isoform 2 expression may be involved in neurectodermal differentiation. The presence of the additional 21 amino acids changes the hydrophobicity and secondary structure of the GRD region [<xref ref-type="bibr" rid="scirp.90548-ref15">15</xref>] . Therefore, alternative splicing disorders may be related to tumor formation. The 4 isoforms of the NF1 gene are therefore the target of numerous genetic anomalies and the highly variable clinical feature may also be due to aberration affecting the NF1 mRNA mature editing process [<xref ref-type="bibr" rid="scirp.90548-ref16">16</xref>] .</p></sec><sec id="s2"><title>2. Diagnosis</title><p>Neurofibromatosis type 1 is diagnosed based on clinical criteria established by the National Institute of Health (NIH) Consensus Development Conference in 1987 (<xref ref-type="table" rid="table1">Table 1</xref>) [<xref ref-type="bibr" rid="scirp.90548-ref17">17</xref>] and updated in 1997 [<xref ref-type="bibr" rid="scirp.90548-ref18">18</xref>] . In addition, members of the United Kingdom Neurofibromatosis Association Clinical Advisory Board collaborated to produce a consensus statement on the current guidelines for the diagnosis and management of NF-1 [<xref ref-type="bibr" rid="scirp.90548-ref19">19</xref>] . Genetic testing is inconsistent. The phenotype/genotype correlation is difficult to establish, but patients with a microdeletion affecting the entire NF1 gene have a severe phenotype with recognizable clinical criteria [<xref ref-type="bibr" rid="scirp.90548-ref20">20</xref>] . This subpopulation develops neurofibromas at an earlier age, have more craniofacial deformities sometimes accompanied with a decreased IQ, and develop malignant nerve-sheat tumors [<xref ref-type="bibr" rid="scirp.90548-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref23">23</xref>] . For other NF-1 patients, the signs may be less profound, but enough to diagnose the disease (<xref ref-type="table" rid="table1">Table 1</xref>). In addition, neurofibromatosis is a neurocristopathy: Neural crest cells and the tissues that arise from them exhibit defects in development [<xref ref-type="bibr" rid="scirp.90548-ref24">24</xref>] . Since the oral cavity is derived from the neural crest [<xref ref-type="bibr" rid="scirp.90548-ref25">25</xref>] , patients with neurofibromatosis type 1 typically exhibit oral disease. In fact, Shapiro et al. found that 72% of NF-1 patients exhibited oral deformities (n = 22) [<xref ref-type="bibr" rid="scirp.90548-ref26">26</xref>] .</p><p>The objective of this review is to analyze the literature regarding oral manifestations in neurofibromatosis type 1, specifically oral epidermis and mucosa involvement, periodontal pathology, maxillary bone and joint lesions, dental disease and deformities, and salivation flow defects. These oral clinical</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> National Institute of Health consensus criteria for diagnosis of neurofibromatosis type 1. Neurofibromatosis type 1 is diagnosed based on clinical criteria established by the National Institute of Health (NIH) Consensus Development Conference in 1987 (<xref ref-type="table" rid="table1">Table 1</xref>) [<xref ref-type="bibr" rid="scirp.90548-ref17">17</xref>] and updated in 1997 [<xref ref-type="bibr" rid="scirp.90548-ref18">18</xref>] </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Two or more of the following clinical features are sufficient to establish a diagnosis of neurofibromatosis type 1:</th></tr></thead><tr><td align="center" valign="middle" >• Six or more caf&#233;-au-lait macules &gt;5 mm diameter at the largest diameter children &gt;15 mm diameter in post-pubescent individuals</td></tr><tr><td align="center" valign="middle" >• Axillary freckling or freckling in inguinal regions</td></tr><tr><td align="center" valign="middle" >• Two or more neurofibromas of any type or one or more plexiform neurofibromas</td></tr><tr><td align="center" valign="middle" >• Two or more Lisch nodules</td></tr><tr><td align="center" valign="middle" >• Bone lesion with sphenoid bone dysplasia or thickening of the cortex of the long bones with or without pseudoarthrosis</td></tr><tr><td align="center" valign="middle" >• An optic pathway glioma</td></tr><tr><td align="center" valign="middle" >• A first-degree relative with neurofibromatosis type 1 diagnosed by the above criteria</td></tr></tbody></table></table-wrap><p>signs are either specific to the pathology (caf&#233;-au-lait-macules and neurofibromas) or they are at the origin of nonspecific but consecutive pathologies of the disease (periodontitis, dental caries, dental inclusions, variation of the salivary flow). This is detailed in the chapters below.</p></sec><sec id="s3"><title>3. Oro-Facial Dermal Involvement</title><p>Caf&#233;-au-lait macules are well-defined skin pigmentations whose diameter is between 5 and 50 mm. In NF-1 patients, they can manifest in the facial area (<xref ref-type="fig" rid="fig1">Figure 1</xref>(b)) and trunk, particularly lateral abdomen (<xref ref-type="fig" rid="fig1">Figure 1</xref>(a)), with the lateral abdomen macules being typically larger. Caf&#233;-au-lait macules are well-defined skin pigmentations whose diameter is between 5 and 50 mm. In NF-1 patients, they can manifest in trunk, particularly lateral abdomen (<xref ref-type="fig" rid="fig1">Figure 1</xref>(a)), and in the facial area (<xref ref-type="fig" rid="fig1">Figure 1</xref>(b)). NF-1 patients often exhibit freckles on the oro-facial epidermis, defined as small macules of 1 to 3 mm spread over the skin (<xref ref-type="fig" rid="fig1">Figure 1</xref>(b)). They appear in childhood in 90% of cases beginning around the age of seven-years-old. They typically localize in the underarm, and more often in the inguinal folds. These hyperpigmentation macules are strongly correlated to NF-1 presence, especially when patients exhibit 6 or more macules of 15 mm in adults and 5 mm in children. Such macules are also present in other diseases such as Leopard Syndrome or McCune-Albright Syndrome. Histologically, they are related to basal keratinocyte and melanocyte hyperpigmentation that is caused by presence of numerous giant melanosomes, “macromelanosomes” [<xref ref-type="bibr" rid="scirp.90548-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref28">28</xref>] . Indeed melanogenesis may be disrupted in NF-1 patients [<xref ref-type="bibr" rid="scirp.90548-ref29">29</xref>] . The cause is likely not linked to the Ras activity in melanocytes, but rather to fibroblasts activity. Here, fibroblasts are thought to overproduce Hepatocyte Growth Factor (HGF) and Stem Cell Factor (SCF), affecting epidermal melanocytes [<xref ref-type="bibr" rid="scirp.90548-ref29">29</xref>] . Both freckles and caf&#233;-au-lait spots do not necessarily cause complications [<xref ref-type="bibr" rid="scirp.90548-ref19">19</xref>] . In</p><p>addition to these pigmentations tumors called neurofibromas are common. Orofacial skin may also be affected by cutaneous neurofibromas (<xref ref-type="fig" rid="fig1">Figure 1</xref>(b)). These are benign tumors located on the peripheral nerves and composed of a variety of cell types. They are classified as five subtypes by the World Health Organization (WHO): localized cutaneous, localized intraneural, plexiform, diffuse cutaneous, and soft tissue neurofibromas. Simply put, there are well-defined localized neurofibromas, diffuse neurofibromas and plexiform neurofibromas whose prognosis is more uncertain. Neurofibromas is constituted by Schwann cells, nerve fibers, mast cells and fibroblasts (perineural and endoneuria) in a myxoid matrix [<xref ref-type="bibr" rid="scirp.90548-ref30">30</xref>] . The presence of multiple neurofibromas is one of the features of NF-1 disease. They are rarely present at birth but appear in early childhood and adolescence. Their quantity increases with age and varies from one individual to another. Patients have been found with up to several thousand tumors. Several studies have shown an increase in the volume and number of tumors during puberty and pregnancy [<xref ref-type="bibr" rid="scirp.90548-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref32">32</xref>] . The most common location is skin, though many organs may be involved, such as the larynx, stomach, intestine, kidney, bladder and heart. On the head, the most common sites are neck, scalp, cheeks and oral cavity. Neurofibromas are present in the facial area in 25% of NF-1 patients, and in the oral cavity in 6.5% of patients [<xref ref-type="bibr" rid="scirp.90548-ref33">33</xref>] . Hyperpigmentation of the mucous membranes and neurofibromas are often associated with pathologies of the oral mucosa.</p></sec><sec id="s4"><title>4. Oral Mucosal Pathology</title><p>NF-1 oral mucosal pathology is defined by the presence of soft tissue tumor (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>). In the oral cavity, nodular neurofibromas of the tongue are most common [<xref ref-type="bibr" rid="scirp.90548-ref34">34</xref>] . There, they lead to macroglossia and enlargement of the fungiform papillae [<xref ref-type="bibr" rid="scirp.90548-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref36">36</xref>] . These benign tumors may also be located on the palate [<xref ref-type="bibr" rid="scirp.90548-ref37">37</xref>] , lips [<xref ref-type="bibr" rid="scirp.90548-ref38">38</xref>] and floor of the mouth [<xref ref-type="bibr" rid="scirp.90548-ref38">38</xref>] . Plexiform neurofibromas, which can be considered a diagnostic criterion for NF-1, are rarely located in the oral cavity [<xref ref-type="bibr" rid="scirp.90548-ref30">30</xref>] . They are tumors that extend along the nerves and may encompass multiple nerve branches. They can be superficial or deep and are a major complication of NF-1 due to the deformities and disability they cause. Plexiform neurofibromas may develop into a malignant peripheral nerve sheat tumor which is a highly fatal metastatic cancer. The risk of malignant transformation is estimated between 8% and 13% [<xref ref-type="bibr" rid="scirp.90548-ref39">39</xref>] . In the mouth, fast growth of the tumor may lead to dysphagia and respiratory distress [<xref ref-type="bibr" rid="scirp.90548-ref40">40</xref>] . The treatment is surgery with a possibility of recurrence after the resection. There are a variety of biomarkers for the diagnosis of these oral soft tissue tumors. S-100 expression indicates Schwann cells [<xref ref-type="bibr" rid="scirp.90548-ref41">41</xref>] , and Collagen IV and CD34 positive cells [<xref ref-type="bibr" rid="scirp.90548-ref37">37</xref>] aid the diagnosis. Tuj-1 indicates neuronal involvement [<xref ref-type="bibr" rid="scirp.90548-ref37">37</xref>] . Another biomarker is Glut-1 which marks perineurial cells [<xref ref-type="bibr" rid="scirp.90548-ref42">42</xref>] . Apart from the proliferative anomalies of nervous tissues, other cells can be affected by this unregulated proliferation: that are gingival fibroblasts. Like Schwann cells and melanocytes, gingival</p><p>fibroblasts derive from neural crest and may be affected by NF-1. Pathologies of the oral mucosa are frequently associated with periodontal disease.</p></sec><sec id="s5"><title>5. Periodontal Diseases</title><p>Gingival thickening is widely described in patients with NF-1. The amount of gingival fibroblasts increases, along with the extracellular matrix quantity [<xref ref-type="bibr" rid="scirp.90548-ref43">43</xref>] . The attached gingiva is overgrown and sometimes extends to the interproximal gingiva [<xref ref-type="bibr" rid="scirp.90548-ref44">44</xref>] . But, this gingival swelling shows no signs of inflammation [<xref ref-type="bibr" rid="scirp.90548-ref43">43</xref>] . Some studies described the presence of neurofibromas in gum as 5% prevalence in NF-1 patients [<xref ref-type="bibr" rid="scirp.90548-ref26">26</xref>] . Fibroblasts may play a role in neurofibromas. Gingival fibroblasts have a stem cell subpopulation derived from the neural crest [<xref ref-type="bibr" rid="scirp.90548-ref45">45</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref46">46</xref>] . Therefore, fibroblasts may play a role in NF1 pathology. NF-1 gingiva may exhibit</p><p>pigmented macules, though it is uncommon. These appear at any age without association to race or gender [<xref ref-type="bibr" rid="scirp.90548-ref47">47</xref>] . These pigmentations can be a source of concern for NF-1 patients and can require an optional therapeutic treatment with a CO2 laser, for example [<xref ref-type="bibr" rid="scirp.90548-ref48">48</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref49">49</xref>] . Radiographic analysis of the periodontium shows a high frequency of periapical cemental dysplasia in vital mandibular teeth of patients with NF-1 [<xref ref-type="bibr" rid="scirp.90548-ref50">50</xref>] . The presence of cemental dysplasia is related to gender and only concern female NF-1 patients [<xref ref-type="bibr" rid="scirp.90548-ref50">50</xref>] . Periodontal disease such as periodontitis may affect NF-1 patients. Periodontal attachment loss is associated with high plaque index. It is probably due to poor oral hygiene consecutive with brushing difficulties [<xref ref-type="bibr" rid="scirp.90548-ref51">51</xref>] . The difficulties of removing dental plaque may be due to the teeth malposition caused by jaw malformation.</p></sec><sec id="s6"><title>6. Jaws Lesions and Joint Diseases</title><p>Bone lesions are also a part of the diagnostic criteria [<xref ref-type="bibr" rid="scirp.90548-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref52">52</xref>] . However, not all NF-1 patients may develop these defects. They are more likely to develop bone manifestations than others, particularly in the facial skeleton. All of the facial skeleton can be affected, including the maxilla (<xref ref-type="fig" rid="fig2">Figure 2</xref>), mandible (<xref ref-type="fig" rid="fig3">Figure 3</xref>), and temporomandibular joints [<xref ref-type="bibr" rid="scirp.90548-ref53">53</xref>] . Jaw malformation was characterized by radiology in 28% of NF-1 patients [<xref ref-type="bibr" rid="scirp.90548-ref54">54</xref>] . For the mandible, the possible abnormalities include enlarged mandibular foramina [<xref ref-type="bibr" rid="scirp.90548-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref54">54</xref>] , hypoplasia of the condyle [<xref ref-type="bibr" rid="scirp.90548-ref55">55</xref>] , elongated coronoid process, and notching in the posterior border of the ramus of mandible [<xref ref-type="bibr" rid="scirp.90548-ref56">56</xref>] . As for the maxilla, the zygomatic bone is hypoplasic [<xref ref-type="bibr" rid="scirp.90548-ref55">55</xref>] . The orbital bones may also be affected by dysplasia that often leads to a disfigurement and a narrowed maxillary sinus [<xref ref-type="bibr" rid="scirp.90548-ref57">57</xref>] . There is probably a common pathogenic mechanism responsible for the appearance of bone abnormalities [<xref ref-type="bibr" rid="scirp.90548-ref58">58</xref>] . The NF-1 gene deficiency causes increased osteoclast activity which partly explains the bone lesions [<xref ref-type="bibr" rid="scirp.90548-ref59">59</xref>] . In addition to the genetic etiology, local factors, due to the presence of tumors, explain bone malformations [<xref ref-type="bibr" rid="scirp.90548-ref60">60</xref>] . The presence of plexiform neurofibromas in the trigeminal nerve could lead to jaw malformation [<xref ref-type="bibr" rid="scirp.90548-ref60">60</xref>] . Friedrich et al. lead an investigation by dental panoramic X-ray on forty-eight NF patients. Twenty-nine had jaw malformation. Twenty-four among these twenty nine NF patients had plexiform neurofibromas on the same side of the malformation [<xref ref-type="bibr" rid="scirp.90548-ref60">60</xref>] . As for the temporo-mandibular joints, they are rarely affected by deformities [<xref ref-type="bibr" rid="scirp.90548-ref53">53</xref>] . But the presence of neurofibromas in the location would cause a deformation. A case of neurofibromas in the articular disc of the temporomandibular joint has been reported as causing facial asymmetry and pain [<xref ref-type="bibr" rid="scirp.90548-ref61">61</xref>] . In view of these bone deformations, the teeth, which are formed inside the jaws, can also be affected during their development. Thus dental abnormalities and caries are described by many authors.</p></sec><sec id="s7"><title>7. Dental Abnormalities and Caries</title><p>Many studies described abnormalities in the number of teeth (agenesis, supernumerary teeth), displaced teeth and impacted teeth [<xref ref-type="bibr" rid="scirp.90548-ref54">54</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref60">60</xref>] (<xref ref-type="fig" rid="fig4">Figure 4</xref>). This may be explained by jaw alteration, which can be related to neurofibromas (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>). Indeed, impacted teeth be present in the tumorous side. Facial plexiform neurofibromas may be associated with maxilla and mandible bone alteration, causing severe disfigurement [<xref ref-type="bibr" rid="scirp.90548-ref57">57</xref>] . The presence of plexiform neurofibromas in the oral cavity of NF-1 patients may have an impact on the size of the tooth crown [<xref ref-type="bibr" rid="scirp.90548-ref62">62</xref>] . It has been described that plexiform neurofibromas</p><p>may be associated with aplasia of the mandibular second molar, which increases teeth and jaw asymmetries in NF-1 patients [<xref ref-type="bibr" rid="scirp.90548-ref60">60</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref62">62</xref>] . Also, rotated teeth were found more in NF patients than the control population. As for tooth displacement, NF patients were more affected. It was particularly maxilla lateral teeth, which were displaced into the palate side (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The absence of second molars of patients with plexiform neurofibromas causes asymmetries that can affect the temporomandibular joint [<xref ref-type="bibr" rid="scirp.90548-ref62">62</xref>] . For the orthodontic abnormalities, only Class III molar occurrence is higher [<xref ref-type="bibr" rid="scirp.90548-ref34">34</xref>] . For children, development of primary teeth can be earlier in NF-1 patients [<xref ref-type="bibr" rid="scirp.90548-ref63">63</xref>] . But, another study of 34 Finnish children aged 8 to 17 years with NF-1 showed that dental development timing is not really affected by the disease [<xref ref-type="bibr" rid="scirp.90548-ref64">64</xref>] . As for the dental anomalies like taurodontism or enamel hypoplasia, they are noticed in NF-1 children but the prevalence of these dental anomalies is not significantly different compared to the control population [<xref ref-type="bibr" rid="scirp.90548-ref34">34</xref>] . So, enamel and dentin would not be affected by the disease. As for dental pulp, there is perineural fibrous thickening in NF-1 patient [<xref ref-type="bibr" rid="scirp.90548-ref65">65</xref>] . Also, the dental pulp stem cells of NF-1 patients have a proliferation more pronounced than the control [<xref ref-type="bibr" rid="scirp.90548-ref66">66</xref>] .</p><p>The association between the prevalence of dental caries and neurofibromatosis type 1 is not obvious. For example, the literature shows that the incidence of dental caries is linked to brushing difficulties and poor hygiene of patients. But, dental hygiene awareness programs, implemented in different countries where the studies are carried out, are involved in the results. A Canadian retrospective study of 191 families, in which one member has NF-1, shows that the prevalence of caries was higher in patients with the disease compared to non-affected family [<xref ref-type="bibr" rid="scirp.90548-ref67">67</xref>] . Another Canadian study comparing children with and without NF-1 shows no significant difference in the incidence of dental caries [<xref ref-type="bibr" rid="scirp.90548-ref68">68</xref>] . In contrast, a Finnish study shows that for a population of NF-1 patients less than 35 years, the incidence of caries is less than the control population [<xref ref-type="bibr" rid="scirp.90548-ref69">69</xref>] . Displaced teeth that cause tooth brushing difficulties also promote the development of caries.</p><p>In conclusion, for dental abnormalities and caries, the prevalence of dental caries is associated with the malposition of some teeth due to the malformation of jaws often related to neurofibromas and may explain the difficulties in maintaining dental hygiene. Moreover, saliva that plays a role in the maintenance of oral homeostasis may be affected by the disease. Dental and periodontal diseases can be explained by a change in saliva,</p></sec><sec id="s8"><title>8. Salivary Flow</title><p>The salivary gland, particularly the major glands, may be affected by the NF-1 pathology. Neurofibromas can develop in these glands. The most affected is the parotid [<xref ref-type="bibr" rid="scirp.90548-ref34">34</xref>] . It can affect adult [<xref ref-type="bibr" rid="scirp.90548-ref70">70</xref>] or child [<xref ref-type="bibr" rid="scirp.90548-ref71">71</xref>] . Plexiform neurofibromas can appear in the sublingual gland [<xref ref-type="bibr" rid="scirp.90548-ref72">72</xref>] . There, it is described as a kind of second tongue. The localization of the mass is not favorable because it may provoke a respiratory distress. The presence of plexiform neurofibromas is also described in the submandibular gland [<xref ref-type="bibr" rid="scirp.90548-ref73">73</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref74">74</xref>] [<xref ref-type="bibr" rid="scirp.90548-ref75">75</xref>] . This gland is rarely affected by such a lesion. The salivary flow was compared between NF patients and controls. Hyposalivation affected 59% of NF-1 patient. It is described as 4-fold higher than in the control group [<xref ref-type="bibr" rid="scirp.90548-ref76">76</xref>] . Saliva is a biological fluid possessing antibacterial capacity and buffer systems allowing the maintenance of a neutral pH. So, the decrease of salivary flow would increase risk of carie development and periodontal disease such as periodontitis.</p></sec><sec id="s9"><title>9. Conclusion</title><p>Oral manifestations of NF-1 patients are common due to the presence of neurofibromas in the oral cavity. These may cause bone deformities as well as macroglossia with functional and aesthetic impacts. During routine examination of NF-1 patients’ oral cavity, it is important to look for neurofibromas and to make excisions when it is possible, or to monitor it to prevent a malignant degeneration. The overgrowth of neurofibromas could lead to respiratory distress in this region of the body. Moreover, in NF-1 patients, dental alignment is often disturbed by bone deformities, making oral hygiene more difficult. This is compounded by a possible hyposalivation, which accentuates the risk of developing caries and periodontal disease. The complexity of this disease, its phenotypic variation and its slow evolution make oral cavity studies difficult. But features of NF-1 summarized in this review could help prevent dental, periodontal and mucosal complications for these patients.</p></sec><sec id="s10"><title>Contributorship Statement</title><p>HC wrote and illustrated the review, BF, AB, BM and I.-Y.S helped with writing, and BG planned the study and oversaw the set.</p></sec><sec id="s11"><title>Acknowledgements</title><p>Declared none.</p></sec><sec id="s12"><title>Conflicts of Interest</title><p>No conflicts of interest declared.</p></sec><sec id="s13"><title>Cite this paper</title><p>Cherifi, H., Fournier, B., Berdal, A., McAlpin, B., Sitbon, I.-Y. and Gogly, B. (2019) Oral Manifestations of Neurofibromatosis Type 1. Journal of Cosmetics, Dermatological Sciences and Applications, 9, 41-55. https://doi.org/10.4236/jcdsa.2019.91004</p></sec></body><back><ref-list><title>References</title><ref id="scirp.90548-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Riccardi, V.M. (1992) Neurofibromatosis: Phenotype, Natural History, and Pathogenesis.</mixed-citation></ref><ref id="scirp.90548-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gerber, P.A., Antal, A.S., Neumann, N.J., et al. (2009) Neurofibromatosis. European Journal of Medical Research, 14, 102-105.</mixed-citation></ref><ref id="scirp.90548-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Lammert, M., Friedman, J.M., Kluwe, L., et al. (2005) Prevalence of Neurofibromatosis 1 in German Children at Elementary School Enrollment. Archives of Dermatology, 141, 71-74. &lt;/br&gt;https://doi.org/10.1001/archderm.141.1.71</mixed-citation></ref><ref id="scirp.90548-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">D’Ambrosio, J.A., Langlais, R.P. and Young, R.S. (1988) Jaw and Skull Changes in Neurofibromatosis. Oral Surgery, Oral Medicine, Oral Pathology, 66, 391-396.  
&lt;/br&gt;https://doi.org/10.1016/0030-4220(88)90252-6</mixed-citation></ref><ref id="scirp.90548-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Bottillo, I., Ahlquist, T., Brekke, H., et al. (2009) Germline and Somatic NF1 Mutations in Sporadic and NF1-Associated Malignant Peripheral Nerve Sheath Tumours. The Journal of Pathology, 217, 693-701. &lt;/br&gt;https://doi.org/10.1002/path.2494</mixed-citation></ref><ref id="scirp.90548-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Eisenbarth, I., Beyer, K., Krone, W., et al. (2000) Toward a Survey of Somatic Mutation of the NF1 Gene in Benign Neurofibromas of Patients with Neurofibromatosis Type 1. American Journal of Human Genetics, 66, 393-401.  
&lt;/br&gt;https://doi.org/10.1086/302747</mixed-citation></ref><ref id="scirp.90548-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Thomson, S.A., Fishbein, L. and Wallace, M.R. (2002) NF1 Mutations and Molecular Testing. Journal of Child Neurology, 17, 555-561.  
&lt;/br&gt;https://doi.org/10.1177/088307380201700803</mixed-citation></ref><ref id="scirp.90548-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Daston, M.M., Scrable, H., Nordlund, M., et al. (1992) The Protein Product of the Neurofibromatosis Type 1 Gene Is Expressed at Highest Abundance in Neurons, Schwann Cells, and Oligodendrocytes. Neuron, 8, 415-428.  
&lt;/br&gt;https://doi.org/10.1016/0896-6273(92)90270-N</mixed-citation></ref><ref id="scirp.90548-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Malhotra, R. and Ratner, N. (1994) Localization of Neurofibromin to Keratinocytes and Melanocytes in Developing Rat and Human Skin. Journal of Investigative Dermatology, 102, 812-818. &lt;/br&gt;https://doi.org/10.1111/1523-1747.ep12379925</mixed-citation></ref><ref id="scirp.90548-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Gutmann, D.H., Parada, L.F., Silva, A.J., et al. (2012) Neurofibromatosis Type 1: Modeling CNS Dysfunction. Journal of Neuroscience, 32, 14087-14093.  
&lt;/br&gt;https://doi.org/10.1523/JNEUROSCI.3242-12.2012</mixed-citation></ref><ref id="scirp.90548-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Cichowski, K. and Jacks, T. (2001) NF1 Tumor Suppressor Gene Function: Narrowing the GAP. Cell, 104, 593-604. &lt;/br&gt;https://doi.org/10.1016/S0092-8674(01)00245-8</mixed-citation></ref><ref id="scirp.90548-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cappione, A.J., French, B.L. and Skuse, G.R. (1997) A Potential Role for NF1 mRNA Editing in the Pathogenesis of NF1 Tumors. American Journal of Human Genetics, 60, 305-312.</mixed-citation></ref><ref id="scirp.90548-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Nishi, T., Lee, P.S., Oka, K., et al. (1991) Differential Expression of Two Types of the Neurofibromatosis Type 1 (NF1) Gene Transcripts Related to Neuronal Differentiation. Oncogene, 6, 1555-1559.</mixed-citation></ref><ref id="scirp.90548-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bahuau, M., Vidaud, M. and Vidaud, D. (1997) Génétique et physiopathologie moléculaire. John Libbey Eurotext, 3, 623-628.</mixed-citation></ref><ref id="scirp.90548-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Nishi, T. and Saya, H. (1991) Neurofibromatosis Type 1 (NF1) Gene: Implication in Neuroectodermal Differentiation and Genesis of Brain Tumors. Cancer and Metastasis Reviews, 10, 301-310. &lt;/br&gt;https://doi.org/10.1007/BF00554792</mixed-citation></ref><ref id="scirp.90548-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Skuse, G.R. and Cappione, A.J. (1997) RNA Processing and Clinical Variability in Neurofibromatosis Type 1 (NF1). Human Molecular Genetics, 6, 1707-1712.  
&lt;/br&gt;https://doi.org/10.1093/hmg/6.10.1707</mixed-citation></ref><ref id="scirp.90548-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">National Institutes of Health Consensus Development Conference (1988) Neurofibromatosis. Conference Statement. Archives of Neurology, 45, 575-578.</mixed-citation></ref><ref id="scirp.90548-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Gutmann, D.H., Aylsworth, A., Carey, J.C., et al. (1997) The Diagnostic Evaluation and Multidisciplinary Management of Neurofibromatosis 1 and Neurofibromatosis 2. JAMA, 278, 51-57. &lt;/br&gt;https://doi.org/10.1001/jama.1997.03550010065042</mixed-citation></ref><ref id="scirp.90548-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ferner, R.E., Huson, S.M., Thomas, N., et al. (2007) Guidelines for the Diagnosis and Management of Individuals with Neurofibromatosis 1. Journal of Medical Genetics, 44, 81-88. &lt;/br&gt;https://doi.org/10.1136/jmg.2006.045906</mixed-citation></ref><ref id="scirp.90548-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Cnossen, M.H., van der Est, M.N., Breuning, M.H., et al. (1997) Deletions Spanning the Neurofibromatosis Type 1 Gene: Implications for Genotype-Phenotype Correlations in Neurofibromatosis Type 1? Human Mutation, 9, 458-464.  
&lt;/br&gt;https://doi.org/10.1002/(SICI)1098-1004(1997)9:5&lt;458::AID-HUMU13&gt;3.0.CO;2-1</mixed-citation></ref><ref id="scirp.90548-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Leppig, K.A., Kaplan, P., Viskochil, D., et al. (1997) Familial Neurofibromatosis 1 Microdeletions: Cosegregation with Distinct Facial Phenotype and Early Onset of Cutaneous Neurofibromata. American Journal of Medical Genetics, 73, 197-204.  
&lt;/br&gt;https://doi.org/10.1002/(SICI)1096-8628(1997)73:2&lt;197::AID-AJMG17&gt;3.0.CO;2-P</mixed-citation></ref><ref id="scirp.90548-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">De Raedt, T., Brems, H., Wolkenstein, P., et al. (2003) Elevated Risk for MPNST in NF1 Microdeletion Patients. American Journal of Human Genetics, 72, 1288-1292.  
&lt;/br&gt;https://doi.org/10.1086/374821</mixed-citation></ref><ref id="scirp.90548-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Hyman, S.L., Shores, A. and North, K.N. (2005) The Nature and Frequency of Cognitive Deficits in Children with Neurofibromatosis Type 1. Neurology, 65, 1037-1044. &lt;/br&gt;https://doi.org/10.1212/01.wnl.0000179303.72345.ce</mixed-citation></ref><ref id="scirp.90548-ref24"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bolande</surname><given-names> R.P. </given-names></name>,<etal>et al</etal>. (<year>1981</year>)<article-title>Neurofibromatosis—The Quintessential Neurocristopathy: Pathogenetic Concepts and Relationships</article-title><source> Advances in Neurology</source><volume> 29</volume>,<fpage> 67</fpage>-<lpage>75</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.90548-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Kuratani, S. (2005) Craniofacial Development and the Evolution of the Vertebrates: The Old Problems on a New Background. Zoological Science, 22, 1-19.  
&lt;/br&gt;https://doi.org/10.2108/zsj.22.1</mixed-citation></ref><ref id="scirp.90548-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Shapiro, S.D., Abramovitch, K., Van Dis, M.L., et al. (1984) Neurofibromatosis: Oral and Radiographic Manifestations. Oral Surgery, Oral Medicine, Oral Pathology, 58, 493-498. &lt;/br&gt;https://doi.org/10.1016/0030-4220(84)90350-5</mixed-citation></ref><ref id="scirp.90548-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Jimbow, K., Szabo, G. and Fitzpatrick, T.B. (1973) Ultrastructure of Giant Pigment Granules (Macromelanosomes) in the Cutaneous Pigmented Macules of Neurofibromatosis. Journal of Investigative Dermatology, 61, 300-309.  
&lt;/br&gt;https://doi.org/10.1111/1523-1747.ep12676518</mixed-citation></ref><ref id="scirp.90548-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Martuza, R.L., Philippe, I., Fitzpatrick, T.B., et al. (1985) Melanin Macroglobules as a Cellular Marker of Neurofibromatosis: A Quantitative Study. Journal of Investigative Dermatology, 85, 347-350.  
&lt;/br&gt;https://doi.org/10.1111/1523-1747.ep12276952</mixed-citation></ref><ref id="scirp.90548-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">De Schepper, S., Boucneau, J., Lambert, J., et al. (2005) Pigment Cell-Related Manifestations in Neurofibromatosis Type 1: An Overview. Pigment Cell Research, 18, 13-24. &lt;/br&gt;https://doi.org/10.1111/j.1600-0749.2004.00206.x</mixed-citation></ref><ref id="scirp.90548-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kamra, H.T., Dantkale, S.S., Birla, K., et al. (2013) Plexiform Neurofibroma in the Submandibular Gland Along with Small Diffuse Neurofibroma in the Floor of the Mouth But without Neurofibromatosis-1: A Rare Case Report. Ecancermedicalscience, 7, 313.</mixed-citation></ref><ref id="scirp.90548-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Dugoff, L. and Sujansky, E. (1996) Neurofibromatosis Type 1 and Pregnancy. American Journal of Medical Genetics, 66, 7-10.  
&lt;/br&gt;https://doi.org/10.1002/(SICI)1096-8628(19961202)66:1&lt;7::AID-AJMG2&gt;3.0.CO;2-R</mixed-citation></ref><ref id="scirp.90548-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Cunha, K.S., Barboza, E.P. and Da Fonseca, E.C. (2003) Identification of Growth Hormone Receptor in Localised Neurofibromas of Patients with Neurofibromatosis Type 1. Journal of Clinical Pathology, 56, 758-763.  
&lt;/br&gt;https://doi.org/10.1136/jcp.56.10.758</mixed-citation></ref><ref id="scirp.90548-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Marocchio, L.S., Oliveira, D.T., Pereira, M.C., et al. (2007) Sporadic and Multiple Neurofibromas in the Head and Neck Region: A Retrospective Study of 33 Years. Clinical Oral Investigations, 11, 165-169.  
&lt;/br&gt;https://doi.org/10.1007/s00784-006-0096-6</mixed-citation></ref><ref id="scirp.90548-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Bardellini, E., Amadori, F., Flocchini, P., et al. (2011) Oral Findings in 50 Children with Neurofibromatosis Type 1. A Case Control Study. European Journal of Paediatric Dentistry, 12, 256-260.</mixed-citation></ref><ref id="scirp.90548-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Kumar, D. (2008) Disorders of the Genome Architecture: A Review. Genome Medicine, 2, 69-76. &lt;/br&gt;https://doi.org/10.1007/s11568-009-9028-2</mixed-citation></ref><ref id="scirp.90548-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Bongiorno, M.R., Pistone, G. and Arico, M. (2006) Manifestations of the Tongue in Neurofibromatosis Type 1. Oral Diseases, 12, 125-129.  
&lt;/br&gt;https://doi.org/10.1111/j.1601-0825.2005.01168.x</mixed-citation></ref><ref id="scirp.90548-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Jouhilahti, E.M., Visnapuu, V., Soukka, T., et al. (2012) Oral Soft Tissue Alterations in Patients with Neurofibromatosis. Clinical Oral Investigations, 16, 551-558.  
&lt;/br&gt;https://doi.org/10.1007/s00784-011-0519-x</mixed-citation></ref><ref id="scirp.90548-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Maruyama, M., Fushiki, H. and Watanabe, Y. (2011) Solitary Neurofibroma of the Floor of the Mouth: A Case Report. Case Reports in Otolaryngology, 2011, Article ID: 967896. &lt;/br&gt;https://doi.org/10.1155/2011/967896</mixed-citation></ref><ref id="scirp.90548-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Evans, D.G., Baser, M.E., McGaughran, J., et al. (2002) Malignant Peripheral Nerve Sheath Tumours in Neurofibromatosis 1. Journal of Medical Genetics, 39, 311-314.  
&lt;/br&gt;https://doi.org/10.1136/jmg.39.5.311</mixed-citation></ref><ref id="scirp.90548-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Ozturk, O. and Tutkun, A. (2012) A Case Report of a Malignant Peripheral Nerve Sheath Tumor of the Oral Cavity in Neurofibromatosis Type 1. Case Reports in Otolaryngology, 2012, Article ID: 936735.</mixed-citation></ref><ref id="scirp.90548-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Weiss, S.W., Langloss, J.M. and Enzinger, F.M. (1983) Value of S-100 Protein in the Diagnosis of Soft Tissue Tumors with Particular Reference to Benign and Malignant Schwann Cell Tumors. Laboratory Investigation, 49, 299-308.</mixed-citation></ref><ref id="scirp.90548-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Hirose, T., Tani, T., Shimada, T., et al. (2003) Immunohistochemical Demonstration of EMA/Glut1-Positive Perineurial Cells and CD34-Positive Fibroblastic Cells in Peripheral Nerve Sheath Tumors. Modern Pathology, 16, 293-298.  
&lt;/br&gt;https://doi.org/10.1097/01.MP.0000062654.83617.B7</mixed-citation></ref><ref id="scirp.90548-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Mahajan, A., Dixit, J. and Bhardwaj, A. (2010) Gingival Enlargement in Neurofibromatosis Type 1: A Case Report and Literature Review. The Journal of Contemporary Dental Practice, 11, 57-63.</mixed-citation></ref><ref id="scirp.90548-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Shetty, B., Umesh, Y., Kranti, K., et al. (2013) Periodontal Manifestations of Von Recklinghausen Neuro Fibromatosis. Journal of Indian Society of Periodontology, 17, 253-256. &lt;/br&gt;https://doi.org/10.4103/0972-124X.113092</mixed-citation></ref><ref id="scirp.90548-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Fournier, B.P., Ferre, F.C., Couty, L., et al. (2010) Multipotent Progenitor Cells in Gingival Connective Tissue. Tissue Engineering Part A, 16, 2891-2899.  
&lt;/br&gt;https://doi.org/10.1089/ten.tea.2009.0796</mixed-citation></ref><ref id="scirp.90548-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Hakkinen, L., Larjava, H. and Fournier, B.P. (2014) Distinct Phenotype and Therapeutic Potential of Gingival Fibroblasts. Cytotherapy, 16, 1171-1186.  
&lt;/br&gt;https://doi.org/10.1016/j.jcyt.2014.04.004</mixed-citation></ref><ref id="scirp.90548-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Ozbayrak, S., Dumlu, A. and Ercalik-Yalcinkaya, S. (2000) Treatment of Melanin-Pigmented Gingiva and Oral Mucosa by CO2 Laser. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 90, 14-15.  
&lt;/br&gt;https://doi.org/10.1067/moe.2000.106396</mixed-citation></ref><ref id="scirp.90548-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Yeh, C.J. (1998) Cryosurgical Treatment of Melanin-Pigmented Gingiva. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 86, 660-663.  
&lt;/br&gt;https://doi.org/10.1016/S1079-2104(98)90199-8</mixed-citation></ref><ref id="scirp.90548-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Almas, K. and Sadig, W. (2002) Surgical Treatment of Melanin-Pigmented Gingiva; an Esthetic Approach. Indian Journal of Dental Research, 13, 70-73.</mixed-citation></ref><ref id="scirp.90548-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Visnapuu, V., Peltonen, S., Ellila, T., et al. (2007) Periapical Cemental Dysplasia Is Common in Women with NF1. European Journal of Medical Genetics, 50, 274-280.  
&lt;/br&gt;https://doi.org/10.1016/j.ejmg.2007.04.001</mixed-citation></ref><ref id="scirp.90548-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Doufexi, A., Mina, M. and Ioannidou, E. (2005) Gingival Overgrowth in Children: Epidemiology, Pathogenesis, and Complications. A Literature Review. Journal of Periodontology, 76, 3-10. &lt;/br&gt;https://doi.org/10.1902/jop.2005.76.1.3</mixed-citation></ref><ref id="scirp.90548-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Muller, H. and Slootweg, P.J. (1981) Maxillofacial Deformities in Neurofibromatosis. Journal of Maxillofacial Surgery, 9, 89-95.  
&lt;/br&gt;https://doi.org/10.1016/S0301-0503(81)80022-7</mixed-citation></ref><ref id="scirp.90548-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Lorson, E.L., DeLong, P.E., Osbon, D.B., et al. (1977) Neurofibromatosis with Central Neurofibroma of the Mandible: Review of the Literature and Report of Case. The Journal of Oral Surgery, 35, 733-738.</mixed-citation></ref><ref id="scirp.90548-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Visnapuu, V., Peltonen, S., Tammisalo, T., et al. (2012) Radiographic Findings in the Jaws of Patients with Neurofibromatosis 1. Journal of Oral and Maxillofacial Surgery, 70, 1351-1357. &lt;/br&gt;https://doi.org/10.1016/j.joms.2011.06.204</mixed-citation></ref><ref id="scirp.90548-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Avcu, N., Kansu, O., Uysal, S., et al. (2009) Cranio-Orbital-Temporal Neurofibromatosis with Cerebral Hemiatrophy Presenting as an Intraoral Mass: A Case Report. Journal of the California Dental Association, 37, 119-121.</mixed-citation></ref><ref id="scirp.90548-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Krishnamoorthy, B., Singh, P., Gundareddy, S.N., et al. (2013) Notching in the Posterior Border of the Ramus of Mandible in a Patient with Neurofibromatosis Type I—A Case Report. Journal of Clinical and Diagnostic Research, 7, 2390-2391.  
&lt;/br&gt;https://doi.org/10.7860/JCDR/2013/5952.3534</mixed-citation></ref><ref id="scirp.90548-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Friedrich, R.E., Stelljes, C., Hagel, C., et al. (2010) Dysplasia of the Orbit and Adjacent Bone Associated with Plexiform Neurofibroma and Ocular Disease in 42 NF-1 Patients. Anticancer Research, 30, 1751-1764.</mixed-citation></ref><ref id="scirp.90548-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Alwan, S., Armstrong, L., Joe, H., et al. (2007) Associations of Osseous Abnormalities in Neurofibromatosis 1. American Journal of Medical Genetics Part A, 143, 1326-1333. &lt;/br&gt;https://doi.org/10.1002/ajmg.a.31754</mixed-citation></ref><ref id="scirp.90548-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Stevenson, D.A., Yan, J., He, Y., et al. (2011) Multiple Increased Osteoclast Functions in Individuals with Neurofibromatosis Type 1. American Journal of Medical Genetics Part A, 155, 1050-1059. &lt;/br&gt;https://doi.org/10.1002/ajmg.a.33965</mixed-citation></ref><ref id="scirp.90548-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Friedrich, R.E., Giese, M., Schmelzle, R., et al. (2003) Jaw Malformations plus Displacement and Numerical Aberrations of Teeth in Neurofibromatosis Type 1: A Descriptive Analysis of 48 Patients Based on Panoramic Radiographs and Oral Findings. Journal of Cranio-Maxillofacial Surgery, 31, 1-9.  
&lt;/br&gt;https://doi.org/10.1016/S1010-5182(02)00160-9</mixed-citation></ref><ref id="scirp.90548-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Van Damme, P.A., Freihofer, H.P. and De Wilde, P.C. (1996) Neurofibroma in the Articular Disc of the Temporomandibular Joint: A Case Report. Journal of Cranio-Maxillofacial Surgery, 24, 310-313.  
&lt;/br&gt;https://doi.org/10.1016/S1010-5182(96)80065-5</mixed-citation></ref><ref id="scirp.90548-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Friedrich, R.E., Giese, M., Stelljes, C., et al. (2012) Size of Tooth Crowns and Position of Teeth Concerning the Extension of Facial Plexiform Neurofibroma in Patients with Neurofibromatosis Type 1. Anticancer Research, 32, 2207-2214.</mixed-citation></ref><ref id="scirp.90548-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Lammert, M., Friedrich, R.E., Friedman, J.M., et al. (2007) Early Primary Tooth Eruption in Neurofibromatosis 1 Individuals. European Journal of Oral Sciences, 115, 425-426. &lt;/br&gt;https://doi.org/10.1111/j.1600-0722.2007.00474.x</mixed-citation></ref><ref id="scirp.90548-ref64"><label>64</label><mixed-citation publication-type="other" xlink:type="simple">Jaasaari, P., Visnapuu, V., Nystrom, M., et al. (2012) Dental Age in Patients with Neurofibromatosis 1. European Journal of Oral Sciences, 120, 549-552.  
&lt;/br&gt;https://doi.org/10.1111/j.1600-0722.2012.01000.x</mixed-citation></ref><ref id="scirp.90548-ref65"><label>65</label><mixed-citation publication-type="other" xlink:type="simple">Curtin, J.P. and McCarthy, S.W. (1997) Perineural Fibrous Thickening within the Dental Pulp in Type 1 Neurofibromatosis: A Case Report. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 84, 400-403.  
&lt;/br&gt;https://doi.org/10.1016/S1079-2104(97)90038-X</mixed-citation></ref><ref id="scirp.90548-ref66"><label>66</label><mixed-citation publication-type="other" xlink:type="simple">Almeida, P.N., Souza, G.T., de Souza, C.M., et al. (2015) Proposing the Use of Dental Pulp Stem Cells as a Suitable Biological Model of Neurofibromatosis Type 1. Child’s Nervous System, 31, 7-13. &lt;/br&gt;https://doi.org/10.1007/s00381-014-2599-9</mixed-citation></ref><ref id="scirp.90548-ref67"><label>67</label><mixed-citation publication-type="other" xlink:type="simple">Tucker, T., Birch, P., Savoy, D.M., et al. (2007) Increased Dental Caries in People with Neurofibromatosis 1. Clinical Genetics, 72, 524-527.  
&lt;/br&gt;https://doi.org/10.1111/j.1399-0004.2007.00886.x</mixed-citation></ref><ref id="scirp.90548-ref68"><label>68</label><mixed-citation publication-type="other" xlink:type="simple">Tsang, E.S., Birch, P., Friedman, J.M., et al. (2010) Prevalence of Dental Caries in Children with Neurofibromatosis 1. Clinical Oral Investigations, 14, 479-480.  
&lt;/br&gt;https://doi.org/10.1007/s00784-009-0361-6</mixed-citation></ref><ref id="scirp.90548-ref69"><label>69</label><mixed-citation publication-type="other" xlink:type="simple">Visnapuu, V., Pienihakkinen, K., Peltonen, S., et al. (2011) Neurofibromatosis 1 and Dental Caries. Clinical Oral Investigations, 15, 119-121.  
&lt;/br&gt;https://doi.org/10.1007/s00784-009-0341-x</mixed-citation></ref><ref id="scirp.90548-ref70"><label>70</label><mixed-citation publication-type="other" xlink:type="simple">Malcolm, E.K. and Lopes, M.B. (2002) April 2002: 35-Year-Old Healthy Man with Enlarging Right Parotid Mass. Brain Pathology, 12, 515-621.</mixed-citation></ref><ref id="scirp.90548-ref71"><label>71</label><mixed-citation publication-type="other" xlink:type="simple">Thompson, M., Cheng, L.H., Stewart, J., et al. (2004) A Paediatric Case of a Solitary Fibrous Tumour of the Parotid Gland. International Journal of Pediatric Otorhinolaryngology, 68, 481-487. &lt;/br&gt;https://doi.org/10.1016/j.ijporl.2003.10.023</mixed-citation></ref><ref id="scirp.90548-ref72"><label>72</label><mixed-citation publication-type="other" xlink:type="simple">Yamada, N., Uchinuma, E., Shioya, N., et al. (1992) Plexiform Neurofibromatosis in an Infant. British Journal of Plastic Surgery, 45, 175-176.  
&lt;/br&gt;https://doi.org/10.1016/0007-1226(92)90182-W</mixed-citation></ref><ref id="scirp.90548-ref73"><label>73</label><mixed-citation publication-type="other" xlink:type="simple">Derekoy, S. and Sefali, M. (2000) Plexiform Neurofibroma of the Submandibular Gland. The Journal of Laryngology &amp; Otology, 114, 643-645.  
&lt;/br&gt;https://doi.org/10.1258/0022215001906390</mixed-citation></ref><ref id="scirp.90548-ref74"><label>74</label><mixed-citation publication-type="other" xlink:type="simple">Aribandi, M., Wood, W.E., Elston, D.M., et al. (2006) CT Features of Plexiform Neurofibroma of the Submandibular Gland. American Journal of Neuroradiology, 27, 126-128.</mixed-citation></ref><ref id="scirp.90548-ref75"><label>75</label><mixed-citation publication-type="other" xlink:type="simple">Tsutsumi, T., Oku, T. and Komatsuzaki, A. (1996) Solitary Plexiform Neurofibroma of the Submandibular Salivary Gland. The Journal of Laryngology &amp; Otology, 110, 1173-1175. &lt;/br&gt;https://doi.org/10.1017/S0022215100136072</mixed-citation></ref><ref id="scirp.90548-ref76"><label>76</label><mixed-citation publication-type="other" xlink:type="simple">Cunha, K.S., Rozza-de-Menezes, R.E., Luna, E.B., et al. (2015) High Prevalence of Hyposalivation in Individuals with Neurofibromatosis 1: A Case-Control Study. Orphanet Journal of Rare Diseases, 10, 24.  
&lt;/br&gt;https://doi.org/10.1186/s13023-015-0239-4</mixed-citation></ref></ref-list></back></article>